XPH: TAEST1901 injection has received approval for clinical trials
The subsidiary of XPH, Xiangxue Life Sciences, has received approval from the National Medical Products Administration for the clinical trial application of the new drug TAEST1901 injection. This drug is suitable for the treatment of advanced gastric cancer with the genotype HLA-A*02:01 and positive expression of the tumor antigen AFP
According to the Zhitong Finance APP, ST XPH (300147.SZ) announced that its subsidiary, Xiangxue Life Science Technology (Guangdong) Co., Ltd. (referred to as "Xiangxue Life Science"), has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The clinical trial application for the new drug TAEST1901 injection submitted by Xiangxue Life Science has been granted clinical trial permission. The indication for this drug application is: for the treatment of advanced gastric cancer with a genotype of HLA-A*02:01 and positive expression of tumor antigen AFP
